Work

Enhancing tumor immunity via in vivo cDC1 reprogramming

Year: 2024

Type: article

Abstract: A recent study by Ascic et al. demonstrates that in situ reprogramming of tumor cells into conventional dendritic cell (cDC)-like cells using viral-PIB transcription factors creates an immunogenic tumor microenvironment with T cell recruitment and activation. The study highlights the potential of tumor-specific cancer immunotherapy using in vivo reprogrammed cDCs.

Source: Trends in Immunology

DOI: 10.1016/j.it.2024.11.008

Authors: Yoojung Kwon, Kyunghee Choi

Institution: Washington University in St. Louis

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,030